[Experiences with new tuberculostatics in the treatment of urogenital tuberculosis (capreomycin, ethambutol, rifampicin)].
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D014401:Tuberculosis, Urogenital / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D010455:Peptides; D004977:Ethambutol; D012293:Rifampin
Erfahrungen mit neuen Tuberkulostatika in der Behandlung der Urogenitaltuberkulose (Capreomycin, Ethambutol, Rifampicin)